Fairvalue-Calculator Fairvalue-Calculator
EN DE

PT Diagnos Laboratorium Utama Tbk (DGNS) Fair Value & Analysis

Healthcare · ID · Market cap 269B IDR

Price230.00 IDR
Fair Value50.50 IDR
Upside-78.0%
Quality95/100
Evidence: High Range 37.87 IDR – 65.74 IDR

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

PT Diagnos Laboratorium Utama Tbk (DGNS) currently trades at 230.00 IDR, while our model-based Fair Value estimate is 50.50 IDR — implying the stock looks roughly 78.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

PT Diagnos Laboratorium Utama Tbk provides health services using laboratories in Indonesia. The company offers laboratory tests comprising hemostasis, hepatitis, autoimmune and rheumatology, tumor markers, toxicology, lipid, allergies, TORCH, diabetes, electrolytes-blood gases, respiratory tract infection, pathology anatomy, neonatal screening, hematology, body fluids, feces, specific proteins, DNAnswer genomics, kidney function, liver function, immunology, osteoporosis, thyroid, pharmacogenomic, heart, reproduction and fertility, microbiology, drug monitoring, lungs, gastrointestinal, nutrition and heavy metals, anemia, and other bacteria; genomics; homecare services; and inspection panel tests. It also provides clinical pathology, anatomical pathology, and microbiology laboratory; and corporate health and research services. PT Diagnos Laboratorium Utama Tbk was founded in 2007 and is headquartered in Jakarta Pusat, Indonesia.

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -54% Danaher Corporation (DHR) -54% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -53% Lonza Group (LZAGY) -77% Agilent Technologies, Inc (A) -52%

Frequently asked questions

Is PT Diagnos Laboratorium Utama Tbk (DGNS) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 50.50 IDR versus a price of 230.00 IDR — about −78% (overvalued). Model-based estimate, not financial advice.
What is the fair value of DGNS?
Our 21-model fair value for PT Diagnos Laboratorium Utama Tbk is 50.50 IDR (as of Jun 24, 2026), built from audited fundamentals. The current price is 230.00 IDR.
What is the quality score of DGNS?
PT Diagnos Laboratorium Utama Tbk has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.